Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC
Introduction Clinical decision-making is challenging in patients who undergo cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) when complete cytoreduction is not feasible. Nevertheless, some patients still benefit with long-term survival after incomplete CRS/HIPEC. There is...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2020-12, Vol.27 (13), p.5016-5023 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5023 |
|---|---|
| container_issue | 13 |
| container_start_page | 5016 |
| container_title | Annals of surgical oncology |
| container_volume | 27 |
| creator | Moaven, Omeed Su, Jing Jin, Guangxu Votanopoulos, Konstantinos I. Shen, Perry Mangieri, Christopher O’Neill, Stacey S. Perry, Kathleen C. Levine, Edward A. Miller, Lance D. |
| description | Introduction
Clinical decision-making is challenging in patients who undergo cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) when complete cytoreduction is not feasible. Nevertheless, some patients still benefit with long-term survival after incomplete CRS/HIPEC. There is currently no robust predictive tool that can assist clinical decision-making in this setting.
Methods
We quantified gene expression of 79 appendiceal mucinous neoplasms (AMN) from patients with incomplete CRS/HIPEC (R2 resection) using a custom NanoString gene panel. Using our previously defined, prognostic subtype classification algorithm based on signed nonnegative matrix factorization, we classified AMN cases into three molecular subtypes termed: immune enriched (IE), mixed (M), and oncogene enriched (OE). Kaplan–Meier and Cox proportional hazards analyses were used to associate subtypes and individual genes with overall survival (OS).
Results
Median overall survival (OS) was 7.7 years for IE, 3.6 years for M, and 1.4 years for OE. Compared with IE, OE was associated with significantly lower survival [hazard ratio (HR) 3.64, 95% confidence interval (CI) 1.63–8.13;
p
= 0.0017]. The differences were observed in both low-grade and high-grade tumors. While only two genes were identified to be associated with OS in low-grade tumors, multiple genes were identified to be associated with OS in high-grade tumors, particularly genes with functions in cell cycle/proliferation, mucin production, immune pathways, and cell adhesion/migration.
Conclusion
Genetic signatures have prognostic value in patients with incomplete cytoreduction and provide valuable information to assist clinical and operative decision-making. Unraveling genetic alterations and involved pathways can direct efforts to design novel therapeutic modalities. |
| doi_str_mv | 10.1245/s10434-020-08841-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2427304336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-fea3cc50774a65235f0528e39417ba261bbae02a06db00103af270c1116d318e3</originalsourceid><addsrcrecordid>eNqNkd1rFDEUxQdRbF39B3yQAV8EGXvzNTP7IpShtgsFC-pzyGTvbFNmkzXJtPS_926nrh8P4lMuye8c7skpitcMPjAu1UliIIWsgEMFbStZ1T4pjpmiK1m37CnNULfVktfqqHiR0g0AawSo58WR4A0oxdhx4bvReWfNWK62u5GG7IJPZRjKc_SYnS2_uI03eYqYSufL090O_dpZJEVnvMVYXpEGfU7lncvX5crbQE6Ysezuc4i4nuze8-RidXXWvSyeDWZM-OrxXBTfPp197S6qy8_nq-70srKykbka0AhrFTSNNLXiQg2geItiKVnTG16zvjcI3EC97ikVCDNQIssYq9eCEbgoPs6-u6nf4trSftGMehfd1sR7HYzTf754d6034VY3dSM5BzJ492gQw_cJU9ZblyyOo_EYpqS55PSXUoia0Ld_oTdhip7iEdWwJVcNRVgUfKZsDClFHA7LMND7OvVcp6Y69UOduiXRm99jHCQ_-yOgnYE77MOQLBVh8YAB7KkWli1NwDqXH-rtwuQzSd__v5RoMdOJCL_B-CvkP_b_AYp_zEM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471925752</pqid></control><display><type>article</type><title>Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Moaven, Omeed ; Su, Jing ; Jin, Guangxu ; Votanopoulos, Konstantinos I. ; Shen, Perry ; Mangieri, Christopher ; O’Neill, Stacey S. ; Perry, Kathleen C. ; Levine, Edward A. ; Miller, Lance D.</creator><creatorcontrib>Moaven, Omeed ; Su, Jing ; Jin, Guangxu ; Votanopoulos, Konstantinos I. ; Shen, Perry ; Mangieri, Christopher ; O’Neill, Stacey S. ; Perry, Kathleen C. ; Levine, Edward A. ; Miller, Lance D.</creatorcontrib><description>Introduction
Clinical decision-making is challenging in patients who undergo cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) when complete cytoreduction is not feasible. Nevertheless, some patients still benefit with long-term survival after incomplete CRS/HIPEC. There is currently no robust predictive tool that can assist clinical decision-making in this setting.
Methods
We quantified gene expression of 79 appendiceal mucinous neoplasms (AMN) from patients with incomplete CRS/HIPEC (R2 resection) using a custom NanoString gene panel. Using our previously defined, prognostic subtype classification algorithm based on signed nonnegative matrix factorization, we classified AMN cases into three molecular subtypes termed: immune enriched (IE), mixed (M), and oncogene enriched (OE). Kaplan–Meier and Cox proportional hazards analyses were used to associate subtypes and individual genes with overall survival (OS).
Results
Median overall survival (OS) was 7.7 years for IE, 3.6 years for M, and 1.4 years for OE. Compared with IE, OE was associated with significantly lower survival [hazard ratio (HR) 3.64, 95% confidence interval (CI) 1.63–8.13;
p
= 0.0017]. The differences were observed in both low-grade and high-grade tumors. While only two genes were identified to be associated with OS in low-grade tumors, multiple genes were identified to be associated with OS in high-grade tumors, particularly genes with functions in cell cycle/proliferation, mucin production, immune pathways, and cell adhesion/migration.
Conclusion
Genetic signatures have prognostic value in patients with incomplete cytoreduction and provide valuable information to assist clinical and operative decision-making. Unraveling genetic alterations and involved pathways can direct efforts to design novel therapeutic modalities.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-020-08841-8</identifier><identifier>PMID: 32705511</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Appendiceal Neoplasms - drug therapy ; Appendiceal Neoplasms - therapy ; Appendix ; Cancer ; Cell adhesion ; Cell adhesion & migration ; Cell cycle ; Cell migration ; Chemotherapy ; Chemotherapy, Cancer, Regional Perfusion ; Combined Modality Therapy ; Cytoreduction Surgical Procedures ; Decision making ; Female ; Gastrointestinal cancer ; Gene expression ; Humans ; Hyperthermic Intraperitoneal Chemotherapy ; Life Sciences & Biomedicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mucin ; Oncology ; Patients ; Percutaneous Coronary Intervention ; Peritoneal Neoplasms - genetics ; Peritoneal Neoplasms - therapy ; Peritoneal Surface Malignancy ; Retrospective Studies ; Science & Technology ; Surgery ; Surgical Oncology ; Survival Rate ; Tumors</subject><ispartof>Annals of surgical oncology, 2020-12, Vol.27 (13), p.5016-5023</ispartof><rights>Society of Surgical Oncology 2020</rights><rights>Society of Surgical Oncology 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>10</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000551809800001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c474t-fea3cc50774a65235f0528e39417ba261bbae02a06db00103af270c1116d318e3</citedby><cites>FETCH-LOGICAL-c474t-fea3cc50774a65235f0528e39417ba261bbae02a06db00103af270c1116d318e3</cites><orcidid>0000-0002-0560-0457</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-020-08841-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-020-08841-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,315,782,786,887,27931,27932,28255,41495,42564,51326</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32705511$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moaven, Omeed</creatorcontrib><creatorcontrib>Su, Jing</creatorcontrib><creatorcontrib>Jin, Guangxu</creatorcontrib><creatorcontrib>Votanopoulos, Konstantinos I.</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Mangieri, Christopher</creatorcontrib><creatorcontrib>O’Neill, Stacey S.</creatorcontrib><creatorcontrib>Perry, Kathleen C.</creatorcontrib><creatorcontrib>Levine, Edward A.</creatorcontrib><creatorcontrib>Miller, Lance D.</creatorcontrib><title>Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>ANN SURG ONCOL</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Introduction
Clinical decision-making is challenging in patients who undergo cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) when complete cytoreduction is not feasible. Nevertheless, some patients still benefit with long-term survival after incomplete CRS/HIPEC. There is currently no robust predictive tool that can assist clinical decision-making in this setting.
Methods
We quantified gene expression of 79 appendiceal mucinous neoplasms (AMN) from patients with incomplete CRS/HIPEC (R2 resection) using a custom NanoString gene panel. Using our previously defined, prognostic subtype classification algorithm based on signed nonnegative matrix factorization, we classified AMN cases into three molecular subtypes termed: immune enriched (IE), mixed (M), and oncogene enriched (OE). Kaplan–Meier and Cox proportional hazards analyses were used to associate subtypes and individual genes with overall survival (OS).
Results
Median overall survival (OS) was 7.7 years for IE, 3.6 years for M, and 1.4 years for OE. Compared with IE, OE was associated with significantly lower survival [hazard ratio (HR) 3.64, 95% confidence interval (CI) 1.63–8.13;
p
= 0.0017]. The differences were observed in both low-grade and high-grade tumors. While only two genes were identified to be associated with OS in low-grade tumors, multiple genes were identified to be associated with OS in high-grade tumors, particularly genes with functions in cell cycle/proliferation, mucin production, immune pathways, and cell adhesion/migration.
Conclusion
Genetic signatures have prognostic value in patients with incomplete cytoreduction and provide valuable information to assist clinical and operative decision-making. Unraveling genetic alterations and involved pathways can direct efforts to design novel therapeutic modalities.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Appendiceal Neoplasms - drug therapy</subject><subject>Appendiceal Neoplasms - therapy</subject><subject>Appendix</subject><subject>Cancer</subject><subject>Cell adhesion</subject><subject>Cell adhesion & migration</subject><subject>Cell cycle</subject><subject>Cell migration</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Cancer, Regional Perfusion</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Decision making</subject><subject>Female</subject><subject>Gastrointestinal cancer</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Hyperthermic Intraperitoneal Chemotherapy</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mucin</subject><subject>Oncology</subject><subject>Patients</subject><subject>Percutaneous Coronary Intervention</subject><subject>Peritoneal Neoplasms - genetics</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Peritoneal Surface Malignancy</subject><subject>Retrospective Studies</subject><subject>Science & Technology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkd1rFDEUxQdRbF39B3yQAV8EGXvzNTP7IpShtgsFC-pzyGTvbFNmkzXJtPS_926nrh8P4lMuye8c7skpitcMPjAu1UliIIWsgEMFbStZ1T4pjpmiK1m37CnNULfVktfqqHiR0g0AawSo58WR4A0oxdhx4bvReWfNWK62u5GG7IJPZRjKc_SYnS2_uI03eYqYSufL090O_dpZJEVnvMVYXpEGfU7lncvX5crbQE6Ysezuc4i4nuze8-RidXXWvSyeDWZM-OrxXBTfPp197S6qy8_nq-70srKykbka0AhrFTSNNLXiQg2geItiKVnTG16zvjcI3EC97ikVCDNQIssYq9eCEbgoPs6-u6nf4trSftGMehfd1sR7HYzTf754d6034VY3dSM5BzJ492gQw_cJU9ZblyyOo_EYpqS55PSXUoia0Ld_oTdhip7iEdWwJVcNRVgUfKZsDClFHA7LMND7OvVcp6Y69UOduiXRm99jHCQ_-yOgnYE77MOQLBVh8YAB7KkWli1NwDqXH-rtwuQzSd__v5RoMdOJCL_B-CvkP_b_AYp_zEM</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Moaven, Omeed</creator><creator>Su, Jing</creator><creator>Jin, Guangxu</creator><creator>Votanopoulos, Konstantinos I.</creator><creator>Shen, Perry</creator><creator>Mangieri, Christopher</creator><creator>O’Neill, Stacey S.</creator><creator>Perry, Kathleen C.</creator><creator>Levine, Edward A.</creator><creator>Miller, Lance D.</creator><general>Springer International Publishing</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0560-0457</orcidid></search><sort><creationdate>20201201</creationdate><title>Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC</title><author>Moaven, Omeed ; Su, Jing ; Jin, Guangxu ; Votanopoulos, Konstantinos I. ; Shen, Perry ; Mangieri, Christopher ; O’Neill, Stacey S. ; Perry, Kathleen C. ; Levine, Edward A. ; Miller, Lance D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-fea3cc50774a65235f0528e39417ba261bbae02a06db00103af270c1116d318e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Appendiceal Neoplasms - drug therapy</topic><topic>Appendiceal Neoplasms - therapy</topic><topic>Appendix</topic><topic>Cancer</topic><topic>Cell adhesion</topic><topic>Cell adhesion & migration</topic><topic>Cell cycle</topic><topic>Cell migration</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Cancer, Regional Perfusion</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Decision making</topic><topic>Female</topic><topic>Gastrointestinal cancer</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Hyperthermic Intraperitoneal Chemotherapy</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mucin</topic><topic>Oncology</topic><topic>Patients</topic><topic>Percutaneous Coronary Intervention</topic><topic>Peritoneal Neoplasms - genetics</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Peritoneal Surface Malignancy</topic><topic>Retrospective Studies</topic><topic>Science & Technology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moaven, Omeed</creatorcontrib><creatorcontrib>Su, Jing</creatorcontrib><creatorcontrib>Jin, Guangxu</creatorcontrib><creatorcontrib>Votanopoulos, Konstantinos I.</creatorcontrib><creatorcontrib>Shen, Perry</creatorcontrib><creatorcontrib>Mangieri, Christopher</creatorcontrib><creatorcontrib>O’Neill, Stacey S.</creatorcontrib><creatorcontrib>Perry, Kathleen C.</creatorcontrib><creatorcontrib>Levine, Edward A.</creatorcontrib><creatorcontrib>Miller, Lance D.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moaven, Omeed</au><au>Su, Jing</au><au>Jin, Guangxu</au><au>Votanopoulos, Konstantinos I.</au><au>Shen, Perry</au><au>Mangieri, Christopher</au><au>O’Neill, Stacey S.</au><au>Perry, Kathleen C.</au><au>Levine, Edward A.</au><au>Miller, Lance D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><stitle>ANN SURG ONCOL</stitle><addtitle>Ann Surg Oncol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>27</volume><issue>13</issue><spage>5016</spage><epage>5023</epage><pages>5016-5023</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Introduction
Clinical decision-making is challenging in patients who undergo cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) when complete cytoreduction is not feasible. Nevertheless, some patients still benefit with long-term survival after incomplete CRS/HIPEC. There is currently no robust predictive tool that can assist clinical decision-making in this setting.
Methods
We quantified gene expression of 79 appendiceal mucinous neoplasms (AMN) from patients with incomplete CRS/HIPEC (R2 resection) using a custom NanoString gene panel. Using our previously defined, prognostic subtype classification algorithm based on signed nonnegative matrix factorization, we classified AMN cases into three molecular subtypes termed: immune enriched (IE), mixed (M), and oncogene enriched (OE). Kaplan–Meier and Cox proportional hazards analyses were used to associate subtypes and individual genes with overall survival (OS).
Results
Median overall survival (OS) was 7.7 years for IE, 3.6 years for M, and 1.4 years for OE. Compared with IE, OE was associated with significantly lower survival [hazard ratio (HR) 3.64, 95% confidence interval (CI) 1.63–8.13;
p
= 0.0017]. The differences were observed in both low-grade and high-grade tumors. While only two genes were identified to be associated with OS in low-grade tumors, multiple genes were identified to be associated with OS in high-grade tumors, particularly genes with functions in cell cycle/proliferation, mucin production, immune pathways, and cell adhesion/migration.
Conclusion
Genetic signatures have prognostic value in patients with incomplete cytoreduction and provide valuable information to assist clinical and operative decision-making. Unraveling genetic alterations and involved pathways can direct efforts to design novel therapeutic modalities.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32705511</pmid><doi>10.1245/s10434-020-08841-8</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0560-0457</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2020-12, Vol.27 (13), p.5016-5023 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7674220 |
| source | MEDLINE; SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Appendiceal Neoplasms - drug therapy Appendiceal Neoplasms - therapy Appendix Cancer Cell adhesion Cell adhesion & migration Cell cycle Cell migration Chemotherapy Chemotherapy, Cancer, Regional Perfusion Combined Modality Therapy Cytoreduction Surgical Procedures Decision making Female Gastrointestinal cancer Gene expression Humans Hyperthermic Intraperitoneal Chemotherapy Life Sciences & Biomedicine Male Medicine Medicine & Public Health Middle Aged Mucin Oncology Patients Percutaneous Coronary Intervention Peritoneal Neoplasms - genetics Peritoneal Neoplasms - therapy Peritoneal Surface Malignancy Retrospective Studies Science & Technology Surgery Surgical Oncology Survival Rate Tumors |
| title | Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T21%3A01%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Implications%20of%20Genetic%20Signatures%20in%20Appendiceal%20Cancer%20Patients%20with%20Incomplete%20Cytoreduction/HIPEC&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Moaven,%20Omeed&rft.date=2020-12-01&rft.volume=27&rft.issue=13&rft.spage=5016&rft.epage=5023&rft.pages=5016-5023&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-020-08841-8&rft_dat=%3Cproquest_pubme%3E2427304336%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471925752&rft_id=info:pmid/32705511&rfr_iscdi=true |